Vanrafia (atrasentan) — Highmark
primary immunoglobulin A nephropathy (IgAN) confirmed by biopsy in adults at risk for rapid disease progression (proteinuria ≥ 0.5 g/day)
Initial criteria
- age ≥ 18 years
- diagnosis of primary IgAN confirmed by biopsy
- at risk for rapid disease progression evidenced by proteinuria ≥ 0.5 g/day
- concurrently taking, or has experienced intolerance or contraindication to, a maximally tolerated dose of one of the following: ACE inhibitor OR ARB
Reauthorization criteria
- experienced a reduction in proteinuria from baseline
- concurrently taking, or has experienced contraindication or intolerance to, one of the following: ACE inhibitor OR ARB
Approval duration
12 months